Recruitment And Diversity

1. Assigned Slot Allocation Offers A Fair Solution For Oncology Phase 1 Trials (Part 2) 4/10/2026

   In part two of this series on slot allocation, Nehal Lakhani, MD, Ph.D. proposes assigned slot allocation as an alternative to competitive placement and discusses how the approach might benefit patients and sites.

2. Slot Allocation Is A Problem For Patients And PIs In Phase 1 Oncology Trials (Part 1) 4/10/2026

   Given the shift in the size and scope of oncology Phase 1 trials, cohort management and slot allocation strategies must change, too. Nehal Lakhani, MD, Ph.D. explains why competitive slot allocation is no longer optimal for patients or PIs.

3. Bridging Language And Medicine: Best Practices In French Regulatory Medical Writing 3/27/2026

   Poor translations are not just clunky. They can be risky. Medical-linguistic consultant Farah Ayadi, PharmD, explains its implications for safety, regulatory submissions, and downstream operational or financial outcomes.

4. The Art Of Finding And Keeping The Right KOL 3/18/2026

   Learn from Incyclix CEO Patrick Roberts how the company identifies its KOLs, tailors engagement to their expertise, measures collaboration success, and sustains successful long-term partnerships.

5. PolarityBio Loosens I/E And Taps Many Provider Types To Reach More Patients 3/13/2026

   Discover how PolarityBio widened enrollment criteria and even developed improved delivery model to better serve investigators and patients in its Phase 3 trial for diabetic foot ulcers.

6. How The ACA Subsidy Lapse Could Hurt Clinical Trial Enrollment 3/12/2026

   The relationship between the Affordable Care Act (ACA) enhanced premium subsidies and clinical research isn’t widely understood, so consultant Devra Densmore is clearing things up, including how coverage loss could impact trial enrollment.

7. When A Clinical Trial Surfaces In An AI Chat, What Happens Next? 3/2/2026

   AI is soon becoming the first interpreter of your clinical trial. Understand its implications for enrollment design, screening efficiency, and ultimately program predictability.

8. The Problem With Excluding Children From GLP-1 Trials In The U.S. 2/19/2026

   In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.

9. How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows 2/17/2026

   Learn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.

10. 4 Steps For Representative Enrollment In Rare Disease Trials 2/16/2026

    Discover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.